ClinicalTrials.Veeva

Menu
C

California Liver Research Institute | Pasadena, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Cilofexor
BI 685509
Firsocostat
Selonsertib
Emricasan
Ursodeoxycholic Acid
UDCA
Lenvatinib
ABI-H2158
Cagrilintide

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 42 total trials
Locations recently updated

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Rese...

Enrolling
Nonalcoholic Fatty Liver Disease
Fatty Liver, Nonalcoholic
Drug: Semaglutide
Drug: Placebo

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Enrolling
NASH
Cirrhosis, Liver
Drug: Resmetirom
Drug: Placebo

The primary objective of this study is to evaluate the effect of setanaxib on alkaline phosphatase (ALP) at Week 24 in participants with PBC and with...

Active, not recruiting
Liver Stiffness
Primary Biliary Cholangitis
Drug: Placebo
Drug: Setanaxib

The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic live...

Enrolling
Alcohol-related Liver Disease
Drug: Cagrilintide
Drug: NNC0194-0499 placebo

To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Inco...

Enrolling
Primary Biliary Cholangitis
Drug: Placebo
Drug: Seladelpar 10 mg

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Enrolling
Primary Biliary Cirrhosis
Drug: Seladelpar 5 mg Capsule
Drug: Seladelpar 10 mg Capsule

This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the effi...

Active, not recruiting
Cirrhosis
Prevention of Esophageal Varices
Drug: belapectin
Drug: Placebo

This study will be conducted to assess the safety/tolerability profile of E7386 as a single agent administered orally in participants with selected a...

Active, not recruiting
Advanced Neoplasms
Drug: E7386

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: PTM CILO/FIR
Drug: Cilofexor (CILO)/Firsocostat (FIR)

This phase 2 trial will evaluate the effects of EP547 in subjects with cholestatic pruritus due to Primary Biliary Cholangitis (PBC) or Primary Scler...

Active, not recruiting
Pruritus
Drug: EP547
Drug: Placebo

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling
Overweight and Obesity
Drug: Retatrutide
Drug: Placebo

Trial sponsors

Gilead Sciences logo
T
Boehringer Ingelheim logo
CymaBay Therapeutics logo
Eisai logo
A
C
Merck Sharp & Dohme (MSD) logo
Z
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems